Gilead, Galapagos halt IPF study in latest stumble for blockbuster alliance February 10, 2021 Auto Bot BioPharma, biopharma nl, California, Foster City, Galapagos, Gilead Sciences, Pharma 0 The decision to discontinue all clinical trials for ziritaxestat is the latest setback in a broad alliance between Gilead Sciences and Galapagos. Last year, the FDA rejected a rheumatoid arthritis drug covered under the partnership.